PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
1-Year Return
21.39%
This Quarter Return
+0.32%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$1.83B
AUM Growth
-$176M
(-8.7%)
Cap. Flow
-$119M
Cap. Flow
% of AUM
-6.5%
Top 10 Holdings %
Top 10 Hldgs %
48.51%
Holding
93
New
6
Increased
23
Reduced
12
Closed
14
Top Buys
| 1 |
UnitedHealth
UNH
|
$25.5M |
| 2 |
Amgen
AMGN
|
$25.3M |
| 3 |
Stryker
SYK
|
$20.1M |
| 4 |
Johnson & Johnson
JNJ
|
$18.8M |
| 5 |
Insmed
INSM
|
$16.2M |
Top Sells
| 1 |
Legend Biotech
LEGN
|
$41.2M |
| 2 |
Zimmer Biomet
ZBH
|
$39.6M |
| 3 |
Avantor
AVTR
|
$34.3M |
| 4 |
Veeva Systems
VEEV
|
$27.5M |
| 5 |
iShares Russell 2000 ETF
IWM
|
$20.8M |
Sector Composition
| 1 | Healthcare | 97.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
DexCom
DXCM
$31.7B
| $26.2M | 1.3% |
231,007
+75,129
| +48% | +$8.52M |
|
|
27
Amgen
AMGN
$151B
| $25.3M | 1.25% |
+81,034
| New | +$25.3M |
|
28
IQVIA
IQV
$31.3B
| $23.7M | 1.17% |
111,854
| – | – |
|
29
Molina Healthcare
MOH
$9.26B
| $20.8M | 1.03% |
70,088
| – | – |
|
|
30
Johnson & Johnson
JNJ
$431B
| $18.8M | 0.93% |
+128,825
| New | +$18.8M |
|
31
Praxis Precision Medicines
PRAX
$970M
| $18.7M | 0.93% |
453,146
-24,459
| -5% | -$1.01M |
|
32
Arcellx
ACLX
$4B
| $17.2M | 0.85% |
311,980
+8,770
| +3% | +$484K |
|
|
33
Insmed
INSM
$30.1B
| $16.2M | 0.8% |
+241,315
| New | +$16.2M |
|
34
ESSA Pharma
EPIX
$11M
| $15.6M | 0.77% |
2,965,442
-14,978
| -0.5% | -$78.8K |
|
35
Sarepta Therapeutics
SRPT
$1.93B
| $13.9M | 0.69% |
88,216
+76,925
| +681% | +$12.2M |
|
36
Celcuity
CELC
$2.31B
| $13.7M | 0.68% |
837,002
+340,000
| +68% | +$5.57M |
|
37
Oscar Health
OSCR
$4.75B
| $13.6M | 0.67% |
860,821
| – | – |
|
38
Immunovant
IMVT
$2.81B
| $12.5M | 0.62% |
472,540
| – | – |
|
|
ITCI
39
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $11.7M | 0.58% |
170,400
+71,521
| +72% | +$4.9M |
|
40
Erasca
ERAS
$420M
| $11M | 0.55% |
4,671,774
+2,136,672
| +84% | +$5.04M |
|
|
ADAP
41
Adaptimmune Therapeutics
ADAP
$13.5M
| $10.3M | 0.51% |
10,520,231
+97,096
| +0.9% | +$94.7K |
|
42
Madrigal Pharmaceuticals
MDGL
$9.61B
| $8.4M | 0.42% |
29,973
| – | – |
|
43
Syndax Pharmaceuticals
SNDX
$1.39B
| $7.95M | 0.39% |
387,357
-271,337
| -41% | -$5.57M |
|
44
Werewolf Therapeutics
HOWL
$61.7M
| $7.91M | 0.39% |
3,241,074
+234,340
| +8% | +$572K |
|
45
Caribou Biosciences
CRBU
$172M
| $6.7M | 0.33% |
4,083,372
-2,399,898
| -37% | -$3.94M |
|
|
CMPS
46
Compass Pathways
CMPS
$489M
| $6.58M | 0.33% |
1,089,592
| – | – |
|
47
Waters Corp
WAT
$17.8B
| $5.96M | 0.29% |
20,541
-17,923
| -47% | -$5.2M |
|
48
Xenon Pharmaceuticals
XENE
$2.98B
| $5.87M | 0.29% |
150,554
| – | – |
|
|
CNTA
49
Centessa Pharmaceuticals
CNTA
$2.12B
| $5.74M | 0.28% |
635,643
+320,969
| +102% | +$2.9M |
|
50
Day One Biopharmaceuticals
DAWN
$759M
| $5.47M | 0.27% |
396,644
+41,393
| +12% | +$570K |
|